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In this chapter we look at our divided world and explore issues such as the poverty of 
resources, health care infrastructure, research capability in developing countries, and the 
potential for exploitation that is inherent in this context and can occur through 
international research collaborations.  We do not aim to repeat the well-rehearsed lists of 
ethical issues that can arise in international health research, but instead endeavour to 
grapple with these issues through the lens of the divided world, with an emphasis on the 
central role of the researcher. 
 
In investigating research as we currently conduct it, we engage in descriptive ethics.  But 
we also need to ask how we ought to be acting, which requires exploring systematically 
developed moral theories or normative ethics.  Through the latter, research ethics may 
provide a guide towards changes in behaviour, which may help us understand better the 
nature of our individual and collective roles in international health research. The Nuffield 
Institute of Bioethics has recognized that we have a great deal to do in this area: 
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Many people in the developing world suffer from poor health and reduced life 
expectancy. The role of research that contributes to the development of 
appropriate treatments and disease prevention measures is vital.  However, lack of 
resources and weak infrastructure mean that many researchers in developing 
countries have very limited capacity to conduct their own clinical research. A 
sound ethical framework is a crucial safeguard to avoid possible exploitation of 
research participants in these circumstances (Quote from the Executive Summary 
of Nuffield Institute of Bioethics report on ‘The ethics of research related to 
healthcare in developing countries’ 2005 page xi) (1).    
  
We argue here that ethics in international public health research needs to combine use of 
international understandings and guidelines with a close examination of how humans 
actually function in societies – both their own and in other peoples’. 
  
Science itself is cultural and therefore embedded in a particular historical and social 
milieu (2). Part of the current historical and social milieu is the phenomenon of 
globalization, which has been defined as ‘the process of increasing economic, political 
and social interdependence and global integration that takes place as capital, traded 
goods, persons, concepts, images, ideas and values diffuse across state boundaries' (3). 
This is particularly true in health where social, political, and economic forces are 
widening global inequalities in health leading to decreasing equity in resources, health 
protection, and health care (4). 
  
Often values are being traded, not integrated, and different value systems are coming into 
conflict. This conflict is often linked to the global inequities and social injustice. These 
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divisions and differences need to be taken into account when creating research 
collaborations. Although globalization provides different ways of communicating in 
order to develop research proposals, how each of us should develop these collaborations 
continues to be an ethical question in international research. The creation of successful 
research collaborations and partnerships itself affects both how research subjects and 
communities are treated and how research teams operate (5).  
  
Although low-income countries are gradually developing their own guidelines and ways 
of institutionalising ethics, most of the international research guidelines are currently 
presented within a western framework (6,7,8). We will discuss these changing value 
systems within international research after first looking briefly at international 
developments in research ethics. 
 
History of International Research and Ethical Issues  
Interest in the ethics of international health research accelerated in the early 1990s with 
the growth of international collaborations, led by the CIOMS guidelines and changes to 
the Declaration of Helsinki (9). From an international perspective, it is important to 
understand the history of the development of such guidelines.  
  
Current regulations and guidelines are a direct consequence of research atrocities during 
the Second World War, and have evolved over the past 60 years. The history of research 
ethics shows the importance of remaining conscious to the problems of unethical 
research. By the beginning of the twentieth century the medical codes created by Thomas 
Percival circa 1800 (10) that consisted of the moral virtues of physicians with some 
mention of moral rules, rules of etiquette, and rules of professional conduct (11,12,13) 
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had become the dominant basis of professional ethics in the United States (13,14,15). In 
1947 the British Medical Association (BMA) published its code of ethics, which 
essentially summarised the previous half-century’s work (11).   The Nuremberg and 
Geneva Codes then expressed a new agenda based on the concept of human rights (16), 
and in 1964 the World Medical Association (WMA) published the Helsinki Declaration 
(7).  
  
The Belmont Report of 1978, issued by the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioural Research, went beyond the Nuremberg 
Code (17) and the Helsinki Declaration to focus on informed consent, favorable risk-
benefit ratios, and the need to ensure that vulnerable populations are not targeted for risky 
research (13). The report established the three main ethical principles in clinical research: 
respect for persons, beneficence, and justice (18). 
  
In the 1980s there was an increase in international health research activity. In the early 
1990s, the Council for International Organisation of Medical Sciences (CIOMS) worked 
with the World Health Organization (WHO) to develop two sets of international 
guidelines for international medical research (6,19). Controversies in the late 1990s 
around international HIV and TB trials (20,21) resulted in changes in the Helsinki 
Declaration and the CIOMS guidelines, and led to a working party report from the 
Nuffield Council of Bioethics in London (1,8). 
  
This section outlines the emergence of the field of research ethics within epidemiology 
and other health sciences in the late 20th century.  It shows the dominance of guidelines 
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developed in wealthy Western societies. This links strongly to the dominant models of 
health research conducted internationally, which we discuss in the next section.   
 
Types of Research Being Conducted Internationally 
Research is ‘the systematic investigation into and study of materials, sources … in order 
to establish facts and reach new conclusions’ (Oxford English Dictionary), and science is 
‘the systematic study and knowledge of natural and physical phenomena (Collins English 
Dictionary). Epidemiology is a core discipline within public health research, whose aim 
has been defined as ‘to generate organized community effort to address the public interest 
in health by applying scientific and technical knowledge to prevent disease and promote 
health’ (22).  Epidemiology has further been described as ‘the study of the distribution 
and determinants of health related states or events in specified populations’ (23).  It is a 
quantitative science that is considered by many to be among the most important 
disciplines in public health (22).  Examples of classical epidemiological research include 
cohort studies and case-control studies.  In addition to epidemiology, public health 
research contains many different disciplines and research approaches that includes: 
clinical research (e.g. drug and vaccine trials); laboratory research; social science 
research (qualitative studies); health systems research (inter-disciplinary); and policy 
research (trans-disciplinary). All these disciplines may be used in the creation of 
intervention studies, including clinical trials and community-based trials health services 
and operational research. Operational research has been defined as ‘the application of 
scientific methods of investigation to the study of complex human organisations and 
services’ (24). 
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For some, the most important aspect of research is not the ‘type of research’ being 
conducted but ‘how’ it is conducted and with whom. For example, some believe that 
epidemiology is becoming increasingly divorced from its important role in public 
health policy and practice (25).  One reason is the lack of involvement of 
communities in the research process (26).  These shifting sands have led to the 
creation of the term "popular epidemiology," a process that highlights social structural 
factors and involves social movements (27,28). Popular epidemiology seeks to return 
the knowledge creation process to ordinary people and is committed to assuring that 
the problem defined arises from within the community and that local people function 
as cornerstones in the research process (29,30).  The essence of popular epidemiology 
is its commitment to the sharing of power with the people with and for whom 
researchers work (27). Popular epidemiology is about how we interact as researchers 
and the importance of the management of research studies. The emergence of popular 
epidemiology may in part be derived from some moral problems encountered in 
international research. 
 
How We Develop Research Internationally 
Many research materials report the stages involved in the creation of a research project, 
such as introduction (study plan and ethical considerations), definition of study 
objectives, selection of interventions (if any), allocation of interventions (e.g. randomised 
or not), choice of outcome measure(s), study population (criteria for selection, inclusion, 
exclusion criteria, size and compliance), implementation (community acceptance, staff 
recruitment and training and field organisation, data handling, quality control, and, 
finally, analysis and reporting (31). In addition to these stages, there is also the search for 
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funding, discussions with funding bodies and the creation of links and partnerships with 
local communities and other organizations. 
  
Although some research disciplines (principally qualitative ones) study the process of the 
creation and management of research, little information on this subject had been 
published until recently (32). However, social scientists are now providing important 
insights into research processes in developing countries (33,34,35). Their studies 
highlight the different perspectives, approaches, and beliefs that distinguish international 
researchers and local populations. Little is also known about how Research Ethics 
Committees (RECs) function. A recent group of studies from Mexico, using both 
qualitative and quantitative methods, highlights the importance of structures, actions and 
processes of Mexican RECs, and suggests a need for audit of committees (36,37).  
 
This section outlines very briefly a growing debate within international health research: 
there is now evidence suggesting that researchers are often very distant from research 
subjects – both culturally and in terms of interaction in the research process.  But what 
does this mean for the development of ethics guidelines in international health research 
and how do researchers use the guidelines that exist?    The following section outlines 
some of the current issues in ethical guideline development and implementation.  
 
Guidelines  
When planning research in developing countries, there are now many regulations and 
ethics guidelines for researchers to consult (38). Those available include international 
guidelines and conventions, directives, national laws or guidelines, regulations and 
guidelines for research sponsored by the pharmaceutical industry, guidelines produced by 
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funding agencies, institutional guidelines, and guidelines relating to a specific disease (1). 
These sources highlight the groups of stakeholders involved, which include lawyers, 
sponsors, researchers, civil servants, insurance brokers, study subjects and communities. 
  
Every researcher is responsible for understanding the research process and what is 
required to create, undertake, manage and disseminate information to those people who 
can benefit from the research findings. Guidelines and regulations do not provide a 
simple rational basis for decision-making, but highlight the complexity and difficulty of 
ethical decision-making.  For example, the executive summary from the Nuffield Council 
on Bioethics meeting on research in developing countries in 2004 indicates how difficult 
it was for the committee involved to apply the ethics guidelines: 
‘Delegates emphasised that applying guidance in practice is often fraught with 
difficulty. When the different guidelines are compared, they are markedly 
inconsistent in some areas. For example, the guidelines vary with regard to the 
scope and level of detail of information to be provided in the consent process, the 
obligation to provide a universal standard of care to control groups, the use of 
placebos, and the extent to which research participants are owed access to 
successful therapeutics after research is complete. There is also variation with the 
degree of involvement of the host country in the review process.’(1). 
 
Guidelines need to be interpreted and specified for each research context, and the role 
and the integrity of the researcher is key in the process. Each researcher needs to ensure, 
on a minimal level, that the formalities required are completed in the host country as well 
as in the collaborating overseas country.  Researchers need to ask themselves constantly 
whether they believe the research manoeuvre being employed is ethical.   Regulations 
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and guidelines will provide assistance in this iterative process, but the decision-making 
ultimately is every party's responsibility.   While research ethics are important in every 
context, they become particularly crucial when the balance of power between the 
researcher and the researched is skewed to the extent that we see in international research 
undertaken in low-income countries.  The next section discusses this. 
 
Ethical Issues in International Research in Low-income Countries 
This section identifies and presents some key ethical issues that arise in international 
research. The controversy over the role of the drug Tenofovir in the prevention of 
HIV provides a story, which illustrates some of the current controversies inherent in 
international health research projects. It highlights the centrality of power dynamics 
within the milieu of different stakeholders and interests that come together in research 
collaborations that link rich with poor.  
 
On Wednesday February 23rd 2005 Andrew Jack of the Financial Times wrote: 
‘Testing Tenofovir on Cameroon prostitutes has landed researchers in a storm of 
criticism’ … The aim of the trial was to test whether Tenofovir could be used to stop 
AIDS infection. Such findings could revolutionise AIDS prevention. But attacks on 
the Cameroon study – and on similar research in half a dozen more countries – have 
raised broader issues about the economics and ethics of clinical trials in developing 
countries while the main beneficiaries are often in richer countries.’ (39) 
 
Tenofovir is a powerful anti-retroviral (ARV) drug (marketed by Gilead) and 
approved for human use in 2001. A number of human studies were planned to 
investigate the drug for pre-exposure prophylaxis against HIV infection (PREP). The 
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countries involved included Botswana, Cambodia, Cameroon, Ghana, Malawi, 
Nigeria, Thailand and the United States. The study was funded by the US National 
Institutes of Health and the Gates Foundation, and planned to recruit 1000 sex 
workers to the trial. The trial was halted in August 2004 ‘… after the Cameroon 
leader judged that future support of trial participants – particularly if they were 
infected with HIV during the trial – was not sufficiently robust.’ (af-
aids@eforums.healthdev.org). 
 
Non-government organisations (NGOs) were also involved in the debate, and a 
representative from Medecins sans Frontieres (MSF) reportedly said: ‘Our concern is 
that these women who become infected receive adequate treatment. They must be 
guaranteed treatment by the trials sponsors’ (39). Following the suspension of the 
trial, the Global Campaign for Microbicides and the AIDS Vaccines Advocacy 
Coalition (AVAC) made its own statement: ‘Recently clinical trials have been 
launched in Africa, Asia and the United States to explore the potential use of oral 
Tenofovir as a ‘once a day’ pill to prevent HIV in uninfected individuals – an 
intervention know as pre-exposure prophylaxis (PREP). Yet concerns from a few 
activists opposed to these efforts have resulted in government decisions to halt the 
trial in Cambodia and the Cameroon.’ (www.avac.org). 
 
The statement from AVAC later invokes assorted beliefs, assumptions and ethical 
imperatives. In a list of five points, AVAC states that the HIV pandemic is creating an 
urgent demand for safe and effective tools to treat HIV infection and to stop 
transmission; that this can only be achieved through responsible credible scientific 
studies; that the rights of vulnerable populations need to be protected; that 
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communities need to be involved in the conceptualisation and implementation of 
scientific studies; that rights of trial subjects need to be respected and that ‘they 
should be admired for their contribution to helping others’. Finally the AVAC 
statement indicated that researchers, and the organisations for whom they work, need 
to be held accountable for their studies.  
 
The Tenofovir story demonstrates the different perspectives of the stakeholders 
involved (study subjects, research groups, NGOs, advocacy groups, governments, 
international agencies), and the overall complexity of the international research 
context. The use of ethics debate in international research collaborations provides a 
tool for presenting different positions, for debating particular research processes, 
while at the same time engaging with the individuals and groups involved in the 
research.    
  
What are the general themes we can derive from the Tenofovir story?    They include: 
social and cultural issues; priority-setting and equity; consent; ethical review of 
research; and standards of care.  Each of these is discussed in turn in the following 
sub-sections.  
 
Social and cultural issues 
By the nature of much work in international health, many researchers move across 
cultures. A society is made up of all the skills, feelings, values, and beliefs that are 
learned, shared, and taught by its members from one generation to the next (40). This 
applies to the local culture of the population to be studied but also to the culture of the 
research team and of the sponsoring agency or national government. Researchers need to 
be asking themselves the following kinds of questions: How much consideration has 
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there been in the process of developing a protocol on social and cultural issues within the 
particular countries involved? Whose perspectives have been respected and considered 
unimportant? Whose perspective has ultimately been felt to be most important? Which 
group has funded the project, and for whom is the work to be conducted? 
  
Crossing social and cultural boundaries challenges our norms, lifestyles and ways of 
seeing the world.  A globalized world requires us to come to grips with the huge 
disparities between the rich and poor. This is an important theme within all international 
health research (4). Is scientific research the most appropriate way to address the health 
problems in a particular country? In the north we often (though not always) think it is, 
and if we have collaborators in the south, then they also may think that it is an 
appropriate approach.  At the same time, they may have different processes and methods 
for conducting the work, which may include different priorities (26). 
 
Priority and equity 
Research in developing countries should be responsive to the health needs and the 
priorities of the community in which it is to be carried out. (Guidelines 8. CIOMS) (6). 
Ninety percent of all medical research conducted is on those diseases that cause 10% of 
the global burden of disease (4,41). Our task as researchers is to ally ourselves with 
approaches that help reduce these inequities because a reduction of inequity produces 
better health (4,42).  Health related research needs to be allied to each country’s health 
priorities. International organizations such as the United Nations (UN), the World Health 
Organization (WHO) and the World Bank identify international health priorities. 
Currently the focus is on the Millenium Development Goals (MDGs) and the reduction of 
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poverty (43), but each country and each research group creates its own priorities within 
these goals and tries to ensure that the goals themselves do not impede creative work.  
  
Although we can speak meaningfully of setting priorities internationally, international 
priorities cannot and should not be the same for each country. Each country has its own 
unique context, its own unique identity and ways of working. Health priorities are 
ultimately created in each country through the government and its relationships with 
international organizations and other stakeholders. However, international research 
groups also influence decision making within countries. The researcher should be asking 
how these priorities are created and who influences these decisions. 
  
Consent 
Research subjects need to understand and give consent to participation in research 
studies, as is discussed by Anna Mastroianni and Jeffrey Kahn in chapter 4. This is 
affected by social and cultural issues (34,44). Guidance from the different bodies agrees 
that each research participant must be adequately informed about the ‘nature, 
significance, implications and risks associated with a research trial,’ and that in the 
majority of cases, informed consent should be sought from each potential research 
participant. Some guidelines stress the importance of respecting cultural beliefs and 
norms, which means that in certain situations community consent may be appropriate, 
though it is important not to assume that individual consent is thereby not required (8).  
The default position should always be individual-subject consent. 
  
International guidelines published by the Council for International Organisations of 
Medical Sciences (CIOMS) 2002, World Medical Association (WMA) 2000, Council of 
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Europe (CoE) 2004, European Union (EU) 2001, European Group on Ethics in Science 
and New Technologies (EGE) 2003, and Nuffield Council on Bioethics (NCOB) 2002 all 
address the issue of consent in international research. The areas they cover include who 
should give consent, how it should be recorded, provision of information, inducements 
and concepts of ‘genuine consent’ (1).  These documents supply a significant body of 
good advice, though it cannot always be taken as authoritative for epidemiology. 
The degree of detail of information required varies between the guidelines and indicates 
the increasing bureaucracy around international trials. For example, the Helsinki 
Declaration of 2000 states that each potential subject must be adequately informed about: 
“The aim of the study and methods to be used, the sources of funding and possible 
conflicts of interest, the institutional affiliations of the researchers; the anticipated 
benefits and potential risks and the follow-up of the study, the discomfort it might entail, 
and the right to abstain from taking part in the study, or to withdraw from it at any time 
without any reprisals” (7). As consent becomes an increasingly bureaucratic process, 
there is a potential to completely miss the point of consent, which is the creation of 
relationship and understanding. 
 
Ethical review of research  
If countries want to be involved in the funds that come through international research 
collaborations they must have functioning research ethics committees. For those of us 
living in wealthy industrialized countries, it is important to remember the long historical 
process that led to the creation of ethics committees in North America and Europe, as 
discussed by Robert Levine in chapter 12. RECs have huge responsibilities that are often 
compromised of their ability to act due to competing interests. As Figure 1 shows, ethical 
decision making involves different tensions that include power equalization, reflection on 
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ethics, reconciliation between personal interest and values, and democratic dialogue 
(13,45). An inappropriate balance in any of these areas will lead to poor decision making 
and unethical research.  It is also clear that local and national RECs are being 
increasingly directed by outside influences, including international regulations as well as 
international research collaborations (46). There is a need to keep this process under 
review and not to assume that ethics committees are able to do the job they were 
established to perform. Sometimes, the process or structure of the committee needs to 
change, and there have been suggestions that regular audit may be needed (36,37). 
 
International guidelines help to clarify the role of RECs. For example, the Helsinki 
Declaration and the International Guidelines for Biomedical Research (CIOMS) have 
established that RECs exist to ensure, that proposed research will not expose participants 
to unacceptable risks and practices.  Also, they must ensure that the potential participants 
can evaluate the expected consequences of their involvement and decide for themselves 
whether to participate (6,7,36). These guidelines state that a REC should operate inside a 
defined framework that includes ‘membership and size of committee, working rules, and 
ethical, legal and regulatory requirements for research on human subjects in the country 
where it is situated as well as applicable international requirements’ (6,7). International 
guidelines stress the importance of the review of scientific research (1), but some 
countries have no established system for review, rendering the maintenance of an ethical 
review process expensive. There is currently a lack of information in many countries 
about the processes and standards of their ethics committees (47,48). 
  
The working party from the Nuffield Council on Bioethics recommended that all 
countries establish an effective system for the ethical review of research that is 
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independent of government and sponsors of research (8). Adequate provision should be 
made for training all professionals involved in the ethics of research. This 
recommendation brings with it a responsibility on the part of industrialized countries to 
help train ethics committees in poorer countries. It also emphasizes the importance of the 
independence of impartially constructed committees. 
 
Standards of care  
In the late 1990s the issue of standards of care was highlighted through the publication of 
clinical trials investigating the prevention of the transmission of HIV from mother to 
child (20,21). This issue relates to the treatment that participants in a control group 
should receive as part of a trial. Some would argue that participants in trials should 
receive the same standard of care as those people in countries sponsoring the research (8). 
But who determines the best standard of care, and which criteria are to be used?   In 
deciding which standard of care is best, the context of the research is critical. As the 
Nuffield Report indicates: ‘The context of the research in different countries must be 
critically assessed to establish whether or not it provides a morally relevant reason for 
offering a different standard of care’ (8). In the quest for equality and equity, it is 
important to realize that people and countries are different and that local socio-political, 
financial, infrastructural, and cultural circumstances are important (9). Equality does not 
mean that people must always be treated identically but that ‘for every difference in the 
way men are treated, a reason should be given that is relevant’. (8,49).  
  
Guidelines have continued to adapt following the revision of the Helsinki Declaration. 
The debate has proved productive and led to several new perspectives. In 2002 the 
Nuffield Council recommended the following: ‘The minimum standard of care that 
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should be offered is the best intervention available as part of the national public health 
system.’(1). 
 
Externally sponsored research 
In many cases funding for international research comes from outside a low-income 
country in which the research is to be carried out. For example, the Tenofovir study (see 
Box 2) was conducted in several different countries and funded by the National Institutes 
of Health (NIH) and the Gates Foundation. This leads to conflicts and tensions around 
control of the processes of research. The ethics review process attempts to deal with some 
of these issues, but each research group and funding agency has a responsibility to ensure 
that individual research subjects are not compromised in the process. Respect for 
difference means that sponsoring agencies need to accept and negotiate various possible 
different approaches to the research process. 
  
The Declaration of Helsinki (Clause 13) stresses the importance of ethics review, but 
does not recognize a special responsibility for ethics review in the host country (9). In 
contrast, the Nuffield Council on Bioethics Report of 2002 recommends that externally 
sponsored research projects be subject to independent ethical review in the sponsor’s 
country in addition to the host country. This ensures that all countries are represented in 
the research ethics discussions.  
  
Current international guidelines provide differing information and stimulate debate 
without providing a solution to various conflicting approaches. A main point of 
disagreement in the guidelines and regulations concerns the degree of involvement of the 
host country in the review process.  The CIOMS guidelines call for representation from 
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host countries, whereas the Council of Europe requires ethical review by an independent 
ethics committee ‘in each State in which any research activity is to take place’ (CoE 2004 
Article 9). The Nuffield Council 2002 recommends that research should be reviewed in 
both the sponsoring country and the host country where research takes place (8). 
  
There is little information available on how these processes actually work. The Nuffield 
Guidelines are useful in providing scenarios to help the reader address the issues in 
particular contexts, but more work is needed to support the research and better understand 
the differing processes. 
 
What happens when the research is over? 
‘Wherever possible, the results of trials where the interventions prove to be 
effective must be translated to improve healthcare for communities in which they 
were undertaken’ (1). 
It is no longer appropriate to conduct research in a particular setting and then simply 
leave with the data. The process of conducting ethical research is about the creation of 
relationships with each of the stakeholders involved including study subjects and 
communities. At the completion of the study there needs to be a clear understanding of 
how the community involved will benefit from the research conducted. For example, in 
the case of Tenofovir (39), important questions include: Will the community receive the 
drug if it is found to be efficacious? Will the placebo group receive the intervention and 
for how long? Who should pay for and supply the treatment or intervention? 
  
As part of the preparation of the protocol there needs to be close collaboration between 
the researcher and the stakeholders, particularly with the communities that are receiving 
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the intervention. These discussions need to be linked to national health priorities and the 
local priorities of those communities. The research needs to be seen as part of a larger 
public health agenda for improving the health of the population. A critical part of the 
engagement must include a precise understanding of investigator responsibility once the 
research is finished.  Consideration of what happens when the research is over is not 
limited to provision of drugs or other interventions after the study has ceased. Thought 
must be given to impact of the research on issues of equity of healthcare provision and 
ongoing issues of capacity building and the training and support of staff. 
 
Conclusions 
When crossing international borders and boundaries it is important to understand that 
particular ways of thinking are not present in all countries. Each context, like each 
individual, is unique.   If we are from a developed country, we may be projecting our 
values onto countries that may have different beliefs and values.  In international health 
research, guidelines and declarations provide us with some information, but each 
researcher and each institution sponsoring research needs to reflect morally on the often 
conflicting advice in order to find his or her own way through the plethora of codes, 
guidelines and recommendations. The whole process of research, from the idea of the 
study, through the development of the protocol, discussions with stakeholders, ethics 
committees, funding activities, the research itself, and the results and the dissemination 
are all points of reflection for each researcher. Each of us needs to be satisfied that our 
contribution, the contribution of our team of researchers, and ultimately with the impact 
of the work on the communities involved can be morally justified. The Nuffield Council 
highlights four principles to use when considering research work related to healthcare in 
developing countries: 1) The duty to alleviate suffering; 2) The duty to show respect for 
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persons; 3) The duty to be sensitive to cultural differences; and 4) The duty not to exploit 
the vulnerable (8).   
 
Benatar and Singer (4) also suggest a list of requirements to consider for making moral 
progress in international health research.  These include: educating researchers and 
members of research ethics committees about research ethics; ensuring that international 
researchers understand and are sensitive to the social, economic and political milieu that 
frames the context in which their research is taking place; involving members of the host 
country in the design and conduct of the trial; ensuring that trials are of direct relevance 
to the health needs of the host country and that the balance of benefits and burdens of the 
project are fairly distributed; conducting prior evaluation by a local committee or 
governing body of whether the study findings can, and will, be incorporated into the local 
healthcare system; providing subjects with care of treatment they would not ordinarily get 
in the country where the trial is carried out; ensuring existing disparities are not more 
deeply entrenched by inappropriate deflection of local human or material resources away 
from the healthcare system in the host country towards the research project; and ensuring 
that research produces benefits for the practice setting and builds the capacity of 
healthcare professionals in the host country. 
 
These requirements stress the importance of connecting with the values that underpin 
local communities, which are often far from obvious.  The roots of communities are 
essential to understand in the creation of a morally appropriate relationship. We need to 
respect differences and find a way of actively encouraging dialogue, group discussion 
and ultimately translation of information. If we are unable to listen, learn, translate, and 
respect, we will fail to be ethical researchers. We should go beyond our current research 
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ethics approach.  As Benatar and Singer note, ‘There is a need to go beyond the reactive 
research ethics of the past. A new, proactive research ethic must be concerned with the 
greatest ethical challenge – the huge inequities in global health’ (4).  
 
* 
 
In this chapter we have explored the ethical issues that arise in the course of 
undertaking epidemiological and international health research. At the outset we 
explained that it was not our intention to provide another set of ethics guidelines or 
benchmarks for researchers. Already, a number of such documents exist, and we have 
signposted the reader towards these, as well as outlining milestones in the historical 
development of key guidelines. 
 
The chapter has instead focused on ethical issues that the researcher inevitably has to 
grapple with during the conduct of research. These include: how to plan and develop 
international research; the value systems of different cultures and countries; particular 
issues in low-income countries such as those around priority-setting, equity and 
consent; external sponsorship and ethical review of research; and what happens when 
the research is over. 
 
Most significantly, however, we have tried to convey that, although following guidelines 
and adhering to the law are both important, what is perhaps critical is that the researcher 
approaches the research with an open mind and willing heart. There is no replacement 
whatsoever for thoughtfulness, sensitivity, and treating people with respect and dignity. 
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Figure 1 Tensions in ethical decision making (13) 
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